CELLDEX THERAPEUTICS INC

CLDXNASDAQ

🏆 #1947 by market capEarnings Nov 9US Equity

$31.62▲ $0.12 (+0.38%)

Market closed · at close

🔔

Track CLDX

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 0.4%

7d▲ 1.6%

14d▼ 18.3%

30d▼ 20.2%

ytd▲ 16.4%

1y▲ 22.2%

🏦Market Cap

$2.10B

Small Cap

📈Revenue Growth (YoY)

-78.6%

Declining

📊Gross Margin

-56850.9%

Thin

💵FCF Margin

-215908.0%

Thin

⚖️P/S Ratio

18797.1x

Expensive

Otter Score

Good

Trading Snapshot

Day Range: $31.48 – $31.78
52-Week Range: $22.10 – $45.14
Volume: $6.00B
Avg Volume: $4.64B
Shares Outstanding: 66.5M
Next Earnings: Nov 11, 2026

Fundamentals Snapshot

Annual Revenue: $2M
Last Q Revenue: $22,000
P/E Ratio: -7.3
P/S Ratio: 18797.1x
EPS (TTM): $-3.86
Dividend Yield: 0.00%
Dilution (1yr): +0.2%

Why Investors Own CLDX

✓High-growth profile — revenue up +44.1% YoY with expanding US Equity exposure.
✓Healthy economics — 63% gross margin and 11% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

CELLDEX THERAPEUTICS INC

CLDX

Financial Trends

Revenue

$2M▼ −78.6% YoY

Gross Margin

100.0%▼ −104.5% YoY

Operating Income

−$287M▲ +47.3% YoY

Free Cash Flow

−$214M▲ +33.8% YoY

Shares Outstanding

66.5M▲ +0.2% YoY

Net Cash

$27M▲ +$2M YoY

StockOtter · stockotter.space

About CELLDEX THERAPEUTICS INC

Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.

🦦